COMMUNIQUÉS West-GlobeNewswire

Elkedonia renforce son Comité stratégique avec la nomination de Pierre d'Epenoux comme Président indépendant
22/04/2026
Cette nomination renforce la gouvernance d'Elkedonia alors que la société poursuit son développement et prépare ses prochaines étapes de croissance Pierre d'Epenoux est l'ancien Président Directeur Général d'ImCheck [...]
Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
22/04/2026
New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused on pediatric diseases; Ojemda ® (tovorafenib) represents a rare [...]
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
22/04/2026
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of stage 3 Tzield is the [...]
Communiqué de presse : Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants
22/04/2026
Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants L'extension d'approbation inclut les enfants âgés d'un an et plus atteints de diabète de type 1 [...]
Ojemda® approuvé dans l’Union européenne comme première thérapie ciblée pour les enfants atteints de gliome pédiatrique de bas grade (pLGG), en rechute ou réfractaire, indépendamment de l’altération de BRAF
22/04/2026
 Nouvelle option thérapeutique pour des tumeurs cérébrales pédiatriques rares et potentiellement invalidantes Moins de 10 % des nouvelles autorisations de médicaments au cours des cinq dernières années ont porté sur des [...]
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
22/04/2026
Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to three months the target action date for its [...]
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026
22/04/2026
ROCKVILLE, Md. and SUZHOU, China, April 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the [...]
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
22/04/2026
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS Data underscore [...]
Triple Green Farms CBD Gummies Claims Evaluated: The Best CBD Gummy Formula on the Market Under Investigation
22/04/2026
A 2026 informational report on Triple Green Farms CBD Gummies' full spectrum hemp extract formula, how the endocannabinoid system works, what published CBD research supports, pricing and guarantee terms, and what adults [...]
Curiox Biosystems Signs Master Software License Agreement for Enterprise-Scale Pluto Code Deployment
22/04/2026
First master licensing framework for Pluto Code enables a global pharmaceutical organization to expand centrifuge-free automation across its liquid-handling infrastructure without repeated contracting WOBURN, Mass., [...]
pHemmePure Claims Evaluated: Feminine UTI Balance Formula for Vaginal pH Support by Board-Certified Urologist
22/04/2026
pHemmePure outlines its feminine balance supplement approach, full ingredient disclosure, and urinary tract wellness positioning for women over 35 seeking daily pH support in 2026 New York, NY, April 21, 2026 (GLOBE [...]
Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
22/04/2026
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple sclerosis (RMS) Both [...]
RNK Health NAD+ Longevity Therapy Claims Evaluated: The Clinician-Guided NAD Injections & Medication Protocol
22/04/2026
An informational overview of how RNK Health structures its at-home NAD+ injection program for 2026, including telehealth eligibility, compounded medication protocols, pricing from $129/mo, and what to know about [...]
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
21/04/2026
AKY-2519, a miniprotein radioconjugate targeting B7-H3, to be featured in two poster presentations Data facilitate initial understanding of AKY-2519 biodistribution and predicted absorbed doses in tumors and normal [...]
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
21/04/2026
ZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expression Confirmed objective response rate (cORR) of 61% at doses 6.4-9.6 mg/kg in platinum [...]
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
21/04/2026
MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that safety and tolerability data from the ProstACT Global Phase 3 [...]
PharmAla Issues Q2 Financial Statements and Grants Options
21/04/2026
TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
21/04/2026
BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycemia BBO-10203 [...]
Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
21/04/2026
IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the [...]

Pages